S&P 500   4,471.37
DOW   35,294.76
QQQ   368.94
S&P 500   4,471.37
DOW   35,294.76
QQQ   368.94
S&P 500   4,471.37
DOW   35,294.76
QQQ   368.94
S&P 500   4,471.37
DOW   35,294.76
QQQ   368.94

Akoya Biosciences Stock Forecast, Price & News

-0.14 (-1.09 %)
(As of 10/15/2021 04:00 PM ET)
Today's Range
50-Day Range
52-Week Range
Volume103,918 shs
Average Volume131,491 shs
Market Capitalization$471.92 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive AKYA News and Ratings via Email

Sign-up to receive the latest news and ratings for Akoya Biosciences and its competitors with MarketBeat's FREE daily newsletter.

About Akoya Biosciences

Akoya Biosciences, Inc., a life sciences technology company, provides spatial biology solutions focused on transforming discovery and clinical research. The company offers single-cell imaging solutions that allow researchers to phenotype cells with spatial context and visualize how they organize and interact to influence disease progression and treatment response. It provides two distinct solutions, the CODEX and Phenoptics platforms, to serve the diverse needs of researchers across discovery, translational, and clinical research. The company was incorporated in 2015 and is headquartered in Marlborough, Massachusetts.


See More Headlines

Industry, Sector and Symbol

Analytical instruments
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$42.44 million





Market Cap
$471.92 million
Next Earnings Date
11/9/2021 (Estimated)
Not Optionable


Overall MarketRank

1.70 out of 5 stars

Medical Sector

918th out of 1,361 stocks

Analytical Instruments Industry

21st out of 30 stocks

Analyst Opinion: 3.5Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Akoya Biosciences (NASDAQ:AKYA) Frequently Asked Questions

Is Akoya Biosciences a buy right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Akoya Biosciences in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Akoya Biosciences stock.
View analyst ratings for Akoya Biosciences
or view top-rated stocks.

What stocks does MarketBeat like better than Akoya Biosciences?

Wall Street analysts have given Akoya Biosciences a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Akoya Biosciences wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Akoya Biosciences?

Akoya Biosciences saw a increase in short interest in the month of September. As of September 30th, there was short interest totaling 592,000 shares, an increase of 36.9% from the September 15th total of 432,500 shares. Based on an average daily volume of 113,100 shares, the days-to-cover ratio is currently 5.2 days. Approximately 3.7% of the company's stock are short sold.
View Akoya Biosciences' Short Interest

When is Akoya Biosciences' next earnings date?

Akoya Biosciences is scheduled to release its next quarterly earnings announcement on Tuesday, November 9th 2021.
View our earnings forecast for Akoya Biosciences

How were Akoya Biosciences' earnings last quarter?

Akoya Biosciences, Inc. (NASDAQ:AKYA) released its quarterly earnings results on Monday, August, 9th. The company reported ($0.20) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.23) by $0.03. The business had revenue of $13.07 million for the quarter, compared to analyst estimates of $12.46 million.
View Akoya Biosciences' earnings history

What guidance has Akoya Biosciences issued on next quarter's earnings?

Akoya Biosciences updated its FY 2021 earnings guidance on Tuesday, September, 7th. The company provided EPS guidance of for the period. The company issued revenue guidance of $52.50 million-$53 million, compared to the consensus revenue estimate of $52.44 million.

What price target have analysts set for AKYA?

4 brokerages have issued twelve-month price objectives for Akoya Biosciences' shares. Their forecasts range from $23.00 to $28.00. On average, they expect Akoya Biosciences' share price to reach $25.50 in the next year. This suggests a possible upside of 100.8% from the stock's current price.
View analysts' price targets for Akoya Biosciences
or view top-rated stocks among Wall Street analysts.

Who are Akoya Biosciences' key executives?

Akoya Biosciences' management team includes the following people:
  • Mr. Brian McKelligon, Pres, CEO & Director (Age 52)
  • Dr. Garry P. Nolan Ph.D., Co-Founder, Independent Director & Head of the Scientific Advisory Board (Age 59)
  • Dr. Nikolay Samusik Ph.D., Co-Founder
  • Dr. Yury Goltsev Ph.D., Co-Founder & Member of Scientific Advisory Board
  • Mr. Joseph S. Driscoll, Chief Financial Officer (Age 56)
  • Dr. Frederic G. Pla, Chief Operating Officer (Age 62)
  • Mr. Clifford C. Hoyt, VP of Translational & Scientific Affairs
  • Mr. Paul Grass, VP of Sales
  • Dr. Julia Kennedy-Darling Ph.D., Head of CODEX R&D
  • Dr. Niro Ramachandran Ph.D., Chief Bus. Officer (Age 46)

When did Akoya Biosciences IPO?

(AKYA) raised $125 million in an initial public offering on Friday, April 16th 2021. The company issued 6,600,000 shares at a price of $18.00-$20.00 per share. J.P. Morgan, Morgan Stanley, Piper Sandler and Canaccord Genuity served as the underwriters for the IPO.

What is Akoya Biosciences' stock symbol?

Akoya Biosciences trades on the NASDAQ under the ticker symbol "AKYA."

When did Akoya Biosciences' lock-up period expire?

Akoya Biosciences' lock-up period expired on Wednesday, October 13th. Akoya Biosciences had issued 6,580,000 shares in its initial public offering on April 16th. The total size of the offering was $131,600,000 based on an initial share price of $20.00. Shares of the company owned by company insiders and major shareholders are now eligible to be traded as a result of the expiration of the lock-up period.

How do I buy shares of Akoya Biosciences?

Shares of AKYA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Akoya Biosciences' stock price today?

One share of AKYA stock can currently be purchased for approximately $12.70.

How much money does Akoya Biosciences make?

Akoya Biosciences has a market capitalization of $471.92 million and generates $42.44 million in revenue each year.

How many employees does Akoya Biosciences have?

Akoya Biosciences employs 169 workers across the globe.

What is Akoya Biosciences' official website?

The official website for Akoya Biosciences is www.akoyabio.com.

How can I contact Akoya Biosciences?

The company can be reached via phone at 855-896-8401 or via email at [email protected].

This page was last updated on 10/16/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.